Stocktoria

MeiraGTx Holdings plc MGTX

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-06-08 · LEI

MeiraGTx Holdings plc financials (annual)

Revenue
$13.3M $15.6M $37.7M $15.9M $14.0M $33.3M $81.4M 2018201920202021202220232024202520252025
Net income
-$82.9M -$54.7M -$58.0M -$79.6M -$129.6M -$84.0M -$147.8M -$114.2M 2018201920202021202220232024202520252025
Free cash flow
-$70.1M $11.1M -$84.9M -$56.9M -$118.1M -$125.5M -$109.5M -$50.2M 2018201920202021202220232024202520252025

Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2025FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue$81.4M$33.3M$14.0M$15.9M$37.7M$15.6M$13.3M
R&D expense$129.6M$119.5M$103.8M$85.7M$66.7M$33.9M$24.9M$33.6M
Operating income-$106.0M-$164.2M-$137.1M-$116.4M-$72.8M-$62.6M-$58.3M-$78.1M
Interest expense$12.2M$13.3M$13.2M$4.9M$288,000$139,000$48,612$33,429
Income tax$0$0$0$0$0$0$0$0$0-$474,391
Net income-$114.2M-$147.8M-$84.0M-$129.6M-$79.6M-$58.0M-$54.7M-$82.9M
EPS (diluted)$-1.42$-2.12$-1.49$-2.87$-1.80$-1.54
Operating cash flow-$46.4M-$104.5M-$105.4M-$73.1M-$10.5M-$64.0M$20.0M-$58.9M
Free cash flow-$50.2M-$109.5M-$125.5M-$118.1M-$56.9M-$84.9M$11.1M-$70.1M
Cash & equivalents$65.9M$14.8M$32.2M$103.7M$129.6M$115.5M$137.7M$209.5M$227.2M$68.1M
Inventory$314,000$385,000
Total assets$244.4M$189.5M$198.7M$269.8M$326.7M$318.2M$320.2M$363.7M$323.9M$96.9M
Total liabilities$250.2M$230.0M$195.8M$201.9M$188.6M$200.5M$134.8M$125.1M$133.1M$15.8M
Shareholders' equity-$5.8M-$40.6M$3.0M$67.8M$138.2M$117.7M$185.4M$238.6M$190.8M$81.1M

Growth · year-over-year · Revenue CAGR 35.3%

MetricFY2025FY2025FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue growth+137.4%-12.0%-57.8%+142.2%+17.1%
Free cash flow growth-867.2%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.